{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:32:54Z","timestamp":1782513174882,"version":"3.54.5"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T00:00:00Z","timestamp":1500940800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s11064-017-2335-4","type":"journal-article","created":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T04:16:12Z","timestamp":1500956172000},"page":"3033-3040","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Resveratrol Protects Against Vacuous Chewing Movements Induced by Chronic Treatment with Fluphenazine"],"prefix":"10.1007","volume":"42","author":[{"given":"Alcindo","family":"Busanello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline Queiroz","family":"Leal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Ricardo","family":"Peroza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jivago","family":"R\u00f6pke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizete","family":"de Moraes Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catiuscia Molz","family":"de Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Libardoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilda Berenice","family":"de Vargas Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roselei","family":"Fachinetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,25]]},"reference":[{"key":"2335_CR1","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1126\/science.1070532","volume":"296","author":"A Sawa","year":"2002","unstructured":"Sawa A, Snyder S (2002) Schizophrenia: diverse approaches to a complex disease. Science 296:692\u2013695","journal-title":"Science"},{"key":"2335_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.67","author":"RS Kahn","year":"2015","unstructured":"Kahn RS, Sommer IM, Murray RM, Meyer-Lindenberg A, Weinberger DR, Cannon TD, O\u2019Donovan M, Correll CU, Kane JM, Van Os J, Insel TR (2015) Schizophrenia. Nat Rev Dis Primers. doi: 10.1038\/nrdp.2015.67","journal-title":"Nat Rev Dis Primers"},{"key":"2335_CR3","doi-asserted-by":"publisher","first-page":"5093","DOI":"10.2174\/1381612819666131216115417","volume":"20","author":"GL Snyder","year":"2014","unstructured":"Snyder GL, Vanover KE (2014) Intracellular signaling and approaches to the treatment of schizophrenia and associated cognitive impairment. Curr Pharm Des 20:5093\u20135103. doi: 10.2174\/1381612819666131216115417","journal-title":"Curr Pharm Des"},{"key":"2335_CR4","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1126\/science.3854","volume":"192","author":"I Creese","year":"1976","unstructured":"Creese I, Burt D, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481\u2013483","journal-title":"Science"},{"key":"2335_CR5","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/261717a0","volume":"261","author":"P Seeman","year":"1976","unstructured":"Seeman P, Lee T, Chau-Wong M, Wong K (1976) Antipsychotic drug doses and neuroleptic\/dopamine receptors. Nature 261:717\u2013719","journal-title":"Nature"},{"key":"2335_CR6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0893-133X(88)90012-7","volume":"1","author":"A Carlson","year":"1988","unstructured":"Carlson A (1988) The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1:179\u2013186","journal-title":"Neuropsychopharmacology"},{"key":"2335_CR7","first-page":"88","volume":"2","author":"DE Casey","year":"1985","unstructured":"Casey DE (1985) Tardive dyskinesia: reversible and irreversible. Psychopharmacology 2:88\u201397","journal-title":"Psychopharmacology"},{"key":"2335_CR8","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1192\/bjp.122.4.395","volume":"122","author":"GE Crane","year":"1973","unstructured":"Crane GE (1973) Persistent dyskinesia. Br J Psychiatry 122:395\u2013405","journal-title":"Br J Psychiatry"},{"key":"2335_CR9","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1192\/bjp.157.4.585","volume":"157","author":"WM Glazer","year":"1990","unstructured":"Glazer WM, Morgenstern H, Schooler N, Berkman CS, Moore DC (1990) Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br J Psychiatry 157:585\u2013592","journal-title":"Br J Psychiatry"},{"key":"2335_CR10","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S0301-0082(99)00064-7","volume":"61","author":"OA Andreassen","year":"2000","unstructured":"Andreassen OA, J\u00f8rgensen HA (2000) Neurotoxicity associated with neuroleptic induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog Neurobiol 61:525\u2013541. doi: 10.1016\/S0301-0082(99)00064-7","journal-title":"Prog Neurobiol"},{"key":"2335_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/WNF.0000000000000040","volume":"37","author":"MJ Lee","year":"2014","unstructured":"Lee MJ, Lin PY, Chang YY, Chong MY, Lee Y (2014) Antipsychotics-induced tardive syndrome: a retrospective epidemiological study. Clin Neuropharmacol 37:111\u2013115. doi: 10.1097\/WNF.0000000000000040","journal-title":"Clin Neuropharmacol"},{"key":"2335_CR12","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/archpsyc.1982.04290040069010","volume":"39","author":"JM Kane","year":"1982","unstructured":"Kane JM, Smith JM (1982) Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 39:473\u2013481","journal-title":"Arch Gen Psychiatry"},{"key":"2335_CR13","first-page":"177","volume":"151","author":"G Gardos","year":"1983","unstructured":"Gardos G, Cole JO (1983) The prognosis of tardive dyskinesia. Am J Psychiatry 151:177\u2013179","journal-title":"Am J Psychiatry"},{"key":"2335_CR14","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/schbul\/18.4.701","volume":"18","author":"R Yassa","year":"1992","unstructured":"Yassa R, Jeste DV (1992) Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull 18:701\u2013715","journal-title":"Schizophr Bull"},{"key":"2335_CR15","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.2147\/DDDT.S32328","volume":"7","author":"AQ Rana","year":"2013","unstructured":"Rana AQ, Chaudry ZM, Blanchet PJ (2013) New and emerging treatments for symptomatic tardive dyskinesia. Drug Des Devel Ther 7:1329\u20131340. doi: 10.2147\/DDDT.S32328","journal-title":"Drug Des Devel Ther"},{"key":"2335_CR16","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/archpsyc.1991.01810360061009","volume":"48","author":"JB Lohr","year":"1991","unstructured":"Lohr JB (1991) Oxygen free radicals and neuropsychiatric illness. Arch Gen Psychiatry 48:1097\u20131106","journal-title":"Arch Gen Psychiatry"},{"key":"2335_CR17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00023210-200317010-00004","volume":"17","author":"JB Lohr","year":"2003","unstructured":"Lohr JB, Kuczenski R, Niculescu AB (2003) Oxidative mechanisms and tardive dyskinesia. CNS Drugs 17:47\u201362","journal-title":"CNS Drugs"},{"key":"2335_CR18","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrn1883","volume":"7","author":"MBH Youdim","year":"2006","unstructured":"Youdim MBH, Edmondson D, Tripton KF (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7:295\u2013309","journal-title":"Nat Rev Neurosci"},{"key":"2335_CR19","doi-asserted-by":"crossref","first-page":"S287","DOI":"10.1038\/sj.bjp.0706464","volume":"147","author":"MB Youdim","year":"2006","unstructured":"Youdim MB, Bakhle YS (2006) Monoamine oxidase: isoforms and inhibitors in Parkinson\u2019s disease and depressive illness. Br J Pharmacol 147:S287\u2013S296","journal-title":"Br J Pharmacol"},{"key":"2335_CR20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s00213-015-4118-4","volume":"233","author":"CM Freitas De","year":"2015","unstructured":"De Freitas CM, Busanello A, Schaffer LF, Peroza LR, Krum BN, Leal CQ, Ceretta AP, da Rocha JB, Fachinetto R (2015) Behavioral and neurochemical effects induced by reserpine in mice. Psychopharmacology 233:457\u2013467. doi: 10.1007\/s00213-015-4118-4","journal-title":"Psychopharmacology"},{"key":"2335_CR21","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S0006-3223(99)00091-8","volume":"46","author":"P Sachdev","year":"1999","unstructured":"Sachdev P, Saharov T, Cathcart S (1999) The preventative role of antioxidants (selegiline and vitamin E) in a rat model of tardive dyskinesia. Biol Psychiatry 46:1672\u20131681","journal-title":"Biol Psychiatry"},{"key":"2335_CR22","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1089\/ARS.2008.2412","volume":"11","author":"S Pervaiz","year":"2009","unstructured":"Pervaiz S, Holme AL (2009) Resveratrol: its biological targets and functional activity. Antioxid Redox Signal 11:2851\u20132897. doi: 10.1089\/ARS.2008.2412","journal-title":"Antioxid Redox Signal"},{"key":"2335_CR23","doi-asserted-by":"crossref","first-page":"14138","DOI":"10.1073\/pnas.94.25.14138","volume":"94","author":"BD Gehm","year":"1997","unstructured":"Gehm BD, McAndrews JM, Chien P, Jameson JL (1997) Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. PNAS 94:14138\u201314143","journal-title":"PNAS"},{"key":"2335_CR24","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/jnr.10315","volume":"70","author":"S G\u00e9linas","year":"2002","unstructured":"G\u00e9linas S, Martinoli M (2002) Neuroprotective effect of estradiol and phytoestrogens on MPP+-induced cytotoxicity in neuronal PC12 cells. J Neurosci Res 70:90\u201396","journal-title":"J Neurosci Res"},{"key":"2335_CR25","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/j.1749-6632.2010.05857.x","volume":"1215","author":"A Quincozes-Santos","year":"2011","unstructured":"Quincozes-Santos A, Gottfried C (2011) Resveratrol modulates astroglial functions: neuroprotective hypothesis. Ann NY Acad Sci 1215:72\u201378. doi: 10.1111\/j.1749-6632.2010.05857.x","journal-title":"Ann NY Acad Sci"},{"key":"2335_CR26","doi-asserted-by":"crossref","first-page":"6726","DOI":"10.2174\/1381612811319380005","volume":"19","author":"M Pall\u00e0s","year":"2013","unstructured":"Pall\u00e0s M, Porquet D, Vicente A, Sanfeliu C (2013) Resveratrol: new avenues for a natural compound in neuroprotection. Curr Pharm Des 19:6726\u20136731","journal-title":"Curr Pharm Des"},{"key":"2335_CR27","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.bbrc.2006.03.190","volume":"344","author":"M Y\u00e1\u00f1ez","year":"2006","unstructured":"Y\u00e1\u00f1ez M, Fraiz N, Cano E, Orallo F (2006) Inhibitory effects of cis- and trans-resveratrol on noradrenaline and 5-hydroxytryptamine uptake and on monoamine oxidase activity. Biochem Biophys Res Commun 344:688\u2013695","journal-title":"Biochem Biophys Res Commun"},{"key":"2335_CR28","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.neuropharm.2011.10.010","volume":"62","author":"V Di Liberto","year":"2012","unstructured":"Di Liberto V, M\u00e4kel\u00e4 J, Korhonen L, Olivieri M, Tselykh T, M\u00e4lki\u00e4 A, Do Thi H, Belluardo N, Lindholm D, Mud\u00f2 G (2012) Involvement of estrogen receptors in the resveratrol-mediated increase in dopamine transporter in human dopaminergic neurons and in striatum of female mice. Neuropharmacology 62:1011\u20131018. doi: 10.1016\/j.neuropharm.2011.10.010","journal-title":"Neuropharmacology"},{"key":"2335_CR29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/FBP.0b013e328341e9b4","volume":"22","author":"A Busanello","year":"2011","unstructured":"Busanello A, Barbosa NB, Peroza LR, Farias LE, Burger ME, Barreto KP, Fachinetto R (2011) Resveratrol protects against a model of vacuous chewing movements induced by reserpine in mice. Behav Pharmacol 22:71\u201375. doi: 10.1097\/FBP.0b013e328341e9b4","journal-title":"Behav Pharmacol"},{"key":"2335_CR30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.pbb.2012.01.007","volume":"101","author":"A Busanello","year":"2012","unstructured":"Busanello A, Peroza LR, Wagner C, Sudati JH, Pereira RP, Prestes AS, Rocha JB, Fachinetto R, Barbosa NB (2012) Resveratrol reduces vacuous chewing movements induced by acute treatment with fluphenazine. Pharmacol Biochem Behav 101:307\u2013310. doi: 10.1016\/j.pbb.2012.01.007","journal-title":"Pharmacol Biochem Behav"},{"key":"2335_CR31","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00213-007-0831-y","volume":"194","author":"R Fachinetto","year":"2007","unstructured":"Fachinetto R, Villarinho JG, Wagner C, Pereira RP, Puntel RL, Paix\u00e3o MW, Braga AL, Calixto JB, Rocha JB, Ferreira J (2007) Diphenyl diselenide decreases the prevalence of vacuous chewing movements induced by fluphenazine in rats. Psychopharmacology 194:423\u2013432","journal-title":"Psychopharmacology"},{"key":"2335_CR32","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.pnpbp.2007.06.028","volume":"31","author":"R Fachinetto","year":"2007","unstructured":"Fachinetto R, Villarinho JG, Wagner C, Pereira RP, Avila DS, Burger ME, Calixto JB, Rocha JB, Ferreira J (2007) Valeriana officinalis does not alter the orofacial dyskinesia induced by haloperidol in rats: role of dopamine transporter. Prog Neuropsychopharmacol Biol Psychiatry 31:1478\u20131486","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2335_CR33","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.brainresbull.2006.05.002","volume":"70","author":"ME Burger","year":"2006","unstructured":"Burger ME, Fachinetto R, Wagner C, Perottoni J, Pereira RP, Zeni G, Rocha JB (2006) Effects of diphenyl-diselenide on orofacial dyskinesia model in rats. Brain Res Bull 70:165\u2013170. doi: 10.1016\/j.brainresbull.2006.05.002","journal-title":"Brain Res Bull"},{"key":"2335_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pnpbp.2016.08.010","volume":"72","author":"J Lister","year":"2017","unstructured":"Lister J, Andreazza AC, Navaid B, Wilson VS, Teo C, Nesarajah Y, Wilson AA, Nobrega JN, Fletcher PJ, Remington G (2017) Lipoic acid and haloperidol-induced vacuous chewing movements: Implications for prophylactic antioxidant use in tardive dyskinesia. Prog Neuropsychopharmacol Biol Psychiatry 72:23\u201329. doi: 10.1016\/j.pnpbp.2016.08.010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2335_CR35","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1007\/s00702-011-0640-7","volume":"118","author":"RP Pereira","year":"2011","unstructured":"Pereira RP, Fachinetto R, Prestes A, Wagner C, Sudati JH, Boligon AA, Athayde ML, Morsch VM, Rocha JBT (2011) Valeriana officinalis ameliorates vacuous chewing movements induced by reserpine in rats. J Neural Transm 118:1547\u20131557. doi: 10.1007\/s00702-011-0640-7","journal-title":"J Neural Transm"},{"key":"2335_CR36","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/jn\/132.2.257","volume":"132","author":"ME Juan","year":"2002","unstructured":"Juan ME, Vinardell MP, Planas JM (2002) The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J Nutr 132:257\u2013260","journal-title":"J Nutr"},{"key":"2335_CR37","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.pnpbp.2014.04.006","volume":"54","author":"J R\u00f6pke","year":"2014","unstructured":"R\u00f6pke J, Busanello A, Leal CQ, Reis EM, de Freitas CM, Villarinho JG, Figueira FH, Mello CF, Ferreira J, Fachinetto R (2014) Anandamide attenuates haloperidol-induced vacuous chewing movements in rats. Prog Neuropsychopharmacol Biol Psychiatry 54:195\u2013199. doi: 10.1016\/j.pnpbp.2014.04.006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2335_CR38","first-page":"76","volume-title":"Experiments in personality","author":"PL Broadhurst","year":"1960","unstructured":"Broadhurst PL (1960) Experiments in psychogenetics. In: Eysenk HJ (ed) Experiments in personality. Routledge & Kegan Paul, London, p\u00a076"},{"key":"2335_CR39","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/FBP.0b013e3283656d68","volume":"24","author":"EM Reis","year":"2013","unstructured":"Reis EM, R\u00f6pke J, Busanello A, Reckziegel P, Leal CQ, Wagner C, Boligon AA, Athayde ML, Fachinetto R (2013) Effect of Hypericum perforatum on different models of movement disorders in rats. Behav Pharmacol 24:623\u2013627. doi: 10.1097\/FBP.0b013e3283656d68","journal-title":"Behav Pharmacol"},{"key":"2335_CR40","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/syn.890180303","volume":"18","author":"MF Egan","year":"1994","unstructured":"Egan MF, Hurd Y, Hyde TM, Weinberger DR, Wyatt RJ, Kleinman JE (1994) Alterations in mRNA levels of D2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic-induced dyskinesias. Synapse 18:178\u2013189. doi: 10.1002\/syn.890180303","journal-title":"Synapse"},{"key":"2335_CR41","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.neuroscience.2003.08.058","volume":"122","author":"OA Andreassen","year":"2003","unstructured":"Andreassen OA, Ferrante RJ, Aamo TO, Beal MF, Jorgensen HA (2003) Oral dyskinesias and histopathological alterations in substantia nigra after long-term haloperidol treatment of old rats. Neuroscience 122:717\u2013725. doi: 10.1016\/j.neuroscience.2003.08.058","journal-title":"Neuroscience"},{"key":"2335_CR42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.pnpbp.2012.04.007","volume":"39","author":"JG Villarinho","year":"2012","unstructured":"Villarinho JG, Fachinetto R, de Vargas Pinheiro F, da Silva Sant\u2019Anna G, Machado P, Dombrowski PA, da Cunha C, de Almeida Cabrini D, Pinto Martins MA, Gauze Bonacorso H, Zanatta N, Rubin MA, Ferreira J (2012) Antidepressant-like effect of the novel MAO inhibitor 2-(3,4-dimethoxy-phenyl)-4,5-dihydro-1H-imidazole (2-DMPI) in mice. Prog Neuropsychopharmacol Biol Psychiatry 39:31\u201339. doi: 10.1016\/j.pnpbp.2012.04.007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2335_CR43","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/958209","author":"EM Reis","year":"2014","unstructured":"Reis EM, Neto FWS, Cattani VB, Peroza LR, Busanello A, Leal CQ, Boligon AA, Lehmen TF, Libardoni M, Athayde ML, Fachinetto R (2014) Antidepressant-like effect of Ilex paraguariensis in rats. Biomed Res Int. doi: 10.1155\/2014\/958209","journal-title":"Biomed Res Int"},{"key":"2335_CR44","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.indcrop.2015.03.060","volume":"70","author":"DR Oliveira","year":"2015","unstructured":"Oliveira DR, Schaffer LF, Busanello A, Barbosa CP, Peroza LR, Freitas CM, Krum BN, Bressan GN, Boligon AA, Athayde ML, Menezes IRA, Fachinetto R (2015) Silymarin has antioxidant potential and changes the activity of Na+\/K+-ATPase and monoamine oxidase in vitro. Ind Crop Prod 70:347\u2013355. doi: 10.1016\/j.indcrop.2015.03.060","journal-title":"Ind Crop Prod"},{"key":"2335_CR45","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","volume":"193","author":"OH Lowry","year":"1951","unstructured":"Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265\u2013275","journal-title":"J Biol Chem"},{"key":"2335_CR46","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1007\/s00213-014-3582-6","volume":"231","author":"J Lister","year":"2014","unstructured":"Lister J, Nobrega JN, Fletcher PJ, Remington G (2014) Oxidative stress and the antipsychotic-induced vacuous chewing movement model of tardive dyskinesia: evidence for antioxidant-based prevention strategies. Psychopharmacology 231:2237\u20132249. doi: 10.1007\/s00213-014-3582-6","journal-title":"Psychopharmacology"},{"key":"2335_CR47","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/309347a0","volume":"309","author":"L Gunne","year":"1984","unstructured":"Gunne L, H\u00e4ggstr\u00f6m J, Sj\u00f6quist B (1984) Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature 309:347\u2013349","journal-title":"Nature"},{"key":"2335_CR48","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1006\/phrs.1997.0159","volume":"35","author":"S Lee","year":"1997","unstructured":"Lee S, Oh D, Jung S, Kim Y, Cho H, Koh K, Lee Y (1997) Neuroleptic drugs alter the dopamine transporter-mediated uptake and release of dopamine: a possible mechanism for drug-induced tardive dyskinesia. Pharmacol Res 35:447\u2013450","journal-title":"Pharmacol Res"},{"key":"2335_CR49","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.pnpbp.2010.05.001","volume":"34","author":"EN Rizos","year":"2010","unstructured":"Rizos EN, Chatziioannou S, Siafakas N, Douzenis A, Katsantoni E, Mandrapilia A, Bacalis S, Fotiadis C, Lykouras L (2010) Increased striatal dopamine transporter levels, as indicated by a DAT scan, induced by ziprasidone in association to improvement of tardive dyskinesia-a case report. Prog Neuropsychopharmacol Biol Psychiatry 34:1135\u20131136. doi: 10.1016\/j.pnpbp.2010.05.001","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2335_CR50","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00204-015-1451-7","volume":"90","author":"P Reckziegel","year":"2015","unstructured":"Reckziegel P, Chen P, Caito S, Gubert P, Soares FA, Fachinetto R, Aschner M (2015) Extracellular dopamine and alterations on dopamine transporter are related to reserpine toxicity in Caenorhabditis elegans. Arch Toxicol 90:633\u2013645. doi: 10.1007\/s00204-015-1451-7","journal-title":"Arch Toxicol"},{"key":"2335_CR51","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.pnpbp.2008.03.024","volume":"32","author":"J Blanchet","year":"2008","unstructured":"Blanchet J, Longpr\u00e9 F, Bureau G, Morissette M, DiPaolo T, Bronchti G, Martinoli MG (2008) Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice. Prog Neuropsychopharmacol Biol Psychiatry 32:1243\u20131250. doi: 10.1016\/j.pnpbp.2008.03.024","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2335_CR52","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejphar.2008.10.005","volume":"600","author":"F Jin","year":"2008","unstructured":"Jin F, Wu Q, Lu YF, Gong QH, Shi JS (2008) Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson\u2019s disease in rats. Eur J Pharmacol 600:78\u201382. doi: 10.1016\/j.ejphar.2008.10.005","journal-title":"Eur J Pharmacol"},{"key":"2335_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejphar.2010.03.043","volume":"636","author":"F Zhang","year":"2010","unstructured":"Zhang F, Liu J, Shi JS (2010) Anti-inflammatory activities of resveratrol in the brain: role of resveratrol in microglial activation. Eur J Pharmacol 636:1\u20137. doi: 10.1016\/j.ejphar.2010.03.043","journal-title":"Eur J Pharmacol"},{"key":"2335_CR54","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.brainres.2014.05.028","volume":"1573","author":"KM Rose","year":"2014","unstructured":"Rose KM, Parmar MS, Cavanaugh JE (2014) Dietary supplementation with resveratrol protects against striatal dopaminergic deficits produced by in utero LPS exposure. Brain Res 1573:37\u201343. doi: 10.1016\/j.brainres.2014.05.028","journal-title":"Brain Res"},{"key":"2335_CR55","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/BF00589906","volume":"99","author":"AE Kelley","year":"1989","unstructured":"Kelley AE, Bakshi VP, Delfs JM, Lang CG (1989) Cholinergic stimulation of the ventrolateral striatum elicits mouth movements in rats: pharmacological and regional specificity. Psychopharmacology 99:542\u2013549","journal-title":"Psychopharmacology"},{"key":"2335_CR56","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0301-0082(98)00053-7","volume":"56","author":"JD Salamone","year":"1998","unstructured":"Salamone JD, Mayorga AJ, Trevitt JT, Cousins MS, Conlan A, Nawab A (1998). Tremulous jaw movements in rats: a model of Parkinsonian tremor. Prog Neurobiol 56:591\u2013611","journal-title":"Prog Neurobiol"},{"key":"2335_CR57","first-page":"1879","volume":"18","author":"S Marconi","year":"2014","unstructured":"Marconi S, Zwingers T (2014) Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson\u2019s disease. Eur Rev Med Pharmacol Sci 18:1879\u20131882","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2335_CR58","doi-asserted-by":"crossref","first-page":"10923","DOI":"10.1073\/pnas.0601515103","volume":"103","author":"XM Ou","year":"2006","unstructured":"Ou XM, Chen K, Shih JC (2006) Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway. Proc Natl Acad Sci 103:10923\u201310928","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"2335_CR59","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3390\/nu8060353","volume":"8","author":"CS Erdogan","year":"2016","unstructured":"Erdogan CS, Vang O (2016) Challenges in analyzing the biological effects of resveratrol. Nutrients 8(6):353. doi: 10.3390\/nu8060353","journal-title":"Nutrients"},{"key":"2335_CR60","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s11064-013-0981-8","volume":"38","author":"LR Peroza","year":"2013","unstructured":"Peroza LR, Busanello A, Leal CQ, R\u00f6pke J, Boligon AA, Meinerz D, Libardoni M, Athayde ML, Fachinetto R (2013) Bauhinia forficata prevents vacuous chewing movements induced by haloperidol in rats and has antioxidant potential in vitro. Neurochem Res 38:789\u2013796. doi: 10.1007\/s11064-013-0981-8","journal-title":"Neurochem Res"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11064-017-2335-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-017-2335-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-017-2335-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T12:26:18Z","timestamp":1659270378000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11064-017-2335-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,25]]},"references-count":60,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["2335"],"URL":"https:\/\/doi.org\/10.1007\/s11064-017-2335-4","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,25]]}}}